paroxetine has been researched along with lithium in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 9 (42.86) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jørgensen, OS; Mellerup, ET; Plenge, P | 1 |
| Ben-Zeev, A; Lerer, B; Newman, ME | 1 |
| Buus Lassen, J | 1 |
| Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
| Begley, A; Cornes, C; Dew, MA; Frank, E; Hall, M; Houck, PR; Kupfer, DJ; Mazumdar, S; Miller, MD; Mulsant, B; Perel, JM; Reynolds, CF; Shear, MK | 1 |
| Cowen, PJ; McTavish, SF; Williamson, DJ | 1 |
| Bagli, M; Laux, G; Rao, ML; Sobanski, T | 1 |
| Echlin, D; Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Sivakumaran, T; Smith, V | 1 |
| Bauer, M; Meister, W; Müller-Oerlinghausen, B; Zaninelli, R | 1 |
| DeFelice, LJ; Petersen, CI | 1 |
| Blier, P; de Montigny, C; Haddjeri, N; Szabo, ST | 1 |
| Bowden, CL; Evans, DL; Gergel, IP; Gyulai, L; Nemeroff, CB; Oakes, R; Pitts, CD; Sachs, GS | 1 |
| Buysse, DJ; Fagiolini, A; Frank, E; Houck, PR; Kupfer, DJ; Luther, JF | 1 |
| Cusin, C; Lattuada, E; Lilli, R; Lorenzi, C; Rossini, D; Serretti, A; Smeraldi, E; Zanardi, R | 1 |
| Benabarre, A; Colom, F; Goikolea, JM; Martinez-Arán, A; Reinares, M; Torrent, C; Vieta, E | 1 |
| Koyama, T; Suzuki, K | 1 |
| Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM | 1 |
| Shelton, RC; Stahl, SM | 1 |
| Khasanov, NR; Khasanova, DR; Oslopov, VN; Safiullina, AA; Zhitkova, IuV | 1 |
| Lee, TM; So, KF; Tang, SW | 1 |
2 review(s) available for paroxetine and lithium
| Article | Year |
|---|---|
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
[Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Fluvoxamine; Humans; Isoenzymes; Lithium; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2003 |
8 trial(s) available for paroxetine and lithium
| Article | Year |
|---|---|
High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.
Topics: Age Factors; Age of Onset; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Lithium; Male; Nortriptyline; Paroxetine; Perphenazine; Placebos; Psychotherapy; Recurrence; Risk Factors; Treatment Outcome | 1996 |
A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype.
Topics: Adolescent; Adult; Aged; Clinical Protocols; Depressive Disorder; Female; Humans; Lithium; Lofepramine; Male; Middle Aged; Paroxetine; Patient Compliance; Patient Dropouts; Psychiatric Status Rating Scales; Research Design; Treatment Outcome | 1998 |
Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study.
Topics: Adult; Aged; Amitriptyline; Depressive Disorder; Double-Blind Method; Female; Humans; Lithium; Male; Middle Aged; Paroxetine | 1999 |
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
Topics: Adult; Aged; Ambulatory Care; Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipramine; Lithium; Male; Middle Aged; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Valproic Acid | 2001 |
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Antimanic Agents; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lithium; Male; Middle Aged; Monoamine Oxidase; Paroxetine; Pindolol; Polymorphism, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sex Characteristics | 2002 |
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Drug Therapy, Combination; Female; Humans; Lithium; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Risperidone and paroxetine given singly and in combination for bipolar depression.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lithium; Male; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2004 |
11 other study(ies) available for paroxetine and lithium
| Article | Year |
|---|---|
Lithium treatment regimens induce different changes in [3H]paroxetine binding protein and other rat brain proteins.
Topics: Animals; Brain Chemistry; Immunochemistry; Lithium; Male; Nerve Tissue Proteins; Paroxetine; Piperidines; Protein Binding; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta | 1992 |
Chloroamphetamine did not prevent the effects of chronic antidepressants on 5-hydroxytryptamine inhibition of forskolin-stimulated adenylate cyclase in rat hippocampus.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antidepressive Agents; Binding Sites; Cerebral Cortex; Chlorides; Colforsin; Hippocampus; Imipramine; Lithium; Lithium Chloride; Male; p-Chloroamphetamine; Paroxetine; Piperidines; Rats; Serotonin; Synapses; Tetrahydronaphthalenes | 1991 |
Nialamide-induced hypermotility in mice treated with inhibitors of monoamine uptake, 5-HT antagonists and lithium.
Topics: Animals; Diet; Female; Lithium; Mice; Monoamine Oxidase Inhibitors; Motor Activity; Nialamide; Paroxetine; Piperidines; Serotonin Antagonists | 1989 |
Effect of valine on 5-HT neurotransmission and mood.
Topics: 1-Naphthylamine; Adult; Affect; Amino Acids, Branched-Chain; Amitriptyline; Analysis of Variance; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Female; Fenfluramine; Humans; Lithium; Male; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Synaptic Transmission; Valine | 1996 |
Serotonin syndrome after lithium add-on medication to paroxetine.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Drug Interactions; Female; Humans; Lithium; Middle Aged; Paroxetine; Serotonin | 1997 |
Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel.
Topics: Animals; Carrier Proteins; Drosophila; Drosophila Proteins; Female; Lithium; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Nerve Tissue Proteins; Oocytes; Paroxetine; Patch-Clamp Techniques; Rats; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sodium; Xenopus laevis | 1999 |
Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combination; Free Radical Scavengers; Hippocampus; Imipramine; Lithium; Male; Monoamine Oxidase Inhibitors; Paroxetine; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Tranylcypromine | 2000 |
Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lithium; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2001 |
Pharmaceutical drug overdose case reports. From the World Literature.
Topics: Acetaminophen; Adolescent; Adult; Aged; Amlodipine; Child, Preschool; Diphenhydramine; Dizocilpine Maleate; Drug Overdose; Female; Humans; International Normalized Ratio; Lithium; Male; Middle Aged; Paroxetine; Salicylates; Valproic Acid; Warfarin | 2003 |
[Efficacy of adepress (paroxetine) in the treatment of depression in patients with chronic cerebral ischemia in the late recovery phase of ischemic stroke with the estimation of the velocity of passive transmembrane ion transport].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Cognition; Depression; Erythrocyte Membrane; Female; Humans; Ion Transport; Lithium; Male; Middle Aged; Paroxetine; Sodium; Treatment Outcome | 2012 |
Neuroprotection in steroid therapy: a rodent model.
Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Antipsychotic Agents; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Proliferation; Corticosterone; Cyclic AMP Response Element-Binding Protein; Dendrites; Golgi Apparatus; Hippocampus; Lithium; Neurogenesis; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors | 2012 |